Thymulin

Overview

Thymulin, originally described as Facteur Thymique Sérique (FTS), is a nonapeptide secreted by the epithelial cells of the thymus. Bach and colleagues first isolated and sequenced it in 1977, which puts it among the best-defined molecules in thymic biology.

What sets Thymulin apart from almost every related peptide is a single structural quirk: the free peptide is inert. It only becomes biologically active once it captures a zinc ion in a 1:1 ratio, folding into the metallopeptide form that the receptor recognises. That zinc–thymulin coupling ties the compound directly to the wider literature on zinc status and immune function.

One distinction shapes how the literature should be read. Thymulin is not Thymalin, and it is not Thymosin α1. Thymalin is a calf-thymus extract, a mixture of thymic peptides with no single defined structure. Thymosin α1 is a 28-residue peptide with its own research field. The three are routinely conflated in popular discussion. This profile concerns only the defined nonapeptide.

Mechanism of action

A zinc-dependent thymic nonapeptide that promotes T-cell maturation and dampens pro-inflammatory cytokine signalling, mechanistically linked to the p38 pathway.

Zinc-dependent activation

• Activity only emerges in the zinc-bound form; the apopeptide is inert
• A coordinated Zn²⁺ ion locks the peptide into the conformation required for receptor binding
• When zinc is scarce, effective Thymulin activity falls, a link reported in both animal models and human observations

T-cell differentiation

• Drives maturation markers and functions in immature lymphoid cells
• Consistent with its role as a thymic signalling molecule in immune-system development
• Endogenous activity declines alongside thymic involution and with age

Inflammatory modulation

• Across several animal models, Thymulin administration tracks with lower TNF-α and IL-6 and with suppression of the p38 MAPK pathway
• Independent groups have arrived at this anti-inflammatory signal through different experimental routes
• The convergence, rather than any single study, is what gives the mechanism its weight

Research findings

• T-cell maturation (in vitro, mechanistic): induction of differentiation markers in immature lymphoid cells, the original functional characterisation.
• Inflammation in a pulmonary hypertension model: in rats, Thymulin administration tracked with a blunted inflammatory component via IL-6 modulation and p38 suppression (independent group, University of Porto).
• Anti-hyperalgesia in an inflammatory pain model: in rats, Thymulin reduced thermal hyperalgesia and oedema, with suppression of spinal microglia activation and p38, mechanistically convergent with the pulmonary finding.
• Human biomarker data: clinical studies have measured endogenous Thymulin/FTS as a readout of thymic function. This is biomarker work; the compound was not administered as an intervention.

Research context

Thymulin sits on a deep but mostly older evidence base, with roots in the late 1970s. The raw count of 884 PubMed records is misleadingly large: much of that corpus is general thymic biology that mentions Thymulin in passing rather than targeted work on the nonapeptide itself. The curated, on-topic literature is considerably narrower.

Evidence strength varies sharply by category. The biochemistry (sequence, zinc dependence, conformation) is solid and long settled. The interventional work, where Thymulin is administered and an outcome is measured, is preclinical: persuasive within animal models, but confined to them. Mechanistic convergence between independent groups on the p38 axis is a real strength. The clear boundary is the absence of randomised human interventional trials.

Open questions

• Randomised human interventional studies are absent; the human work is largely biomarker-based. This is the obvious next frontier for clinical immunology groups.
• Translation of the animal-model findings into outcomes in humans has not been characterised.
• Zinc dependence complicates both formulation and interpretation: the active species requires zinc in equimolar amounts, which any study design has to account for explicitly.
• Widespread confusion with Thymalin and Thymosin α1 muddies both public discussion and parts of the older literature. Clear nomenclature in future work would help the field considerably.

Research outlook

Controlled human studies that use Thymulin as an intervention with standardised immune readouts, the natural next step for clinical immunology.

Systematic work on the zinc–thymulin axis in the context of immunosenescence. Because Thymulin activity falls with both age and zinc status, it is an unusually well-defined entry point for aging-focused immunology.

Further mechanistic work on the p38 pathway, building on the convergent animal-model findings.

A clear nomenclatural separation of Thymulin from Thymalin and Thymosin α1, so the older literature can be read on its own terms.

Scientific interest

One of the few defined zinc-dependent metallopeptides in immune research, an unusual feature that sets it apart from almost every related peptide.

Exceptionally well characterised for a research peptide: the sequence and mode of action have been settled since 1977, an unusually firm biochemical foundation.

The triangle of zinc status, immune function and aging makes Thymulin a natural reference point for immunosenescence research, a field in which the decline of thymic function is a central question.

Independent groups converging on the same anti-inflammatory p38 mechanism gives the preclinical evidence a coherence that many niche peptides lack.

Specifications

References

1. Biochemical characterisation of a serum thymic factor · Bach JF, Bardenne M, Pleau JM, Rosa J · Nature · 1977
2. Thymic dysfunction in childhood T-cell acute lymphoblastic leukaemia evaluated by serum thymic factor (FTS) determination · Consolini R, Legitimo A, Calleri A, Milani M · Haematologica · 1992
3. Interactions Between Zinc and Thymulin · Dardenne M, Pleau JM · Metal-Based Drugs · 1994
4. Thymulin inhibits monocrotaline-induced pulmonary hypertension modulating interleukin-6 expression and suppressing p38 pathway · Henriques-Coelho T, Brandão-Nogueira A, Moreira-Gonçalves D, Correia-Pinto J, et al. · Endocrinology · 2008
5. Thymulin treatment attenuates inflammatory pain by modulating spinal cellular and molecular signalling pathways · Nasseri B, Zaringhalam J, Daniali S, Manaheji H, Abbasnejad Z, Nazemian V · International Immunopharmacology · 2019

Availability

In stock · Batch PEP-THY-2026-01 · HPLC 98.48 % · released 21 Jun 2026

• Thymulin 20 mg · product page with price and batch CoA